Bedrijf laden
Just reported
Q3 2026 results
From Editas Medicine's results release of 9 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 10,4M
+37% y/y
-13% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ -0,15
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -24,3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 48BA+
EXELExelixis, Inc.US$ 17,3BA+
JAZZJazz Pharmaceuticals plcUS$ 15,9BA
HALOHalozyme Therapeutics, Inc.US$ 11,6BA+
TECHBIO-Techne CorpUS$ 11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Hoe het geld verdient
- Licensing and research collaborations100%
De omzetaandelen zijn schattingen voor FY2025, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt3
EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.
Wie het koopt3
- Bristol Myers Squibb: collaborates on research into gene-edited immune-cell treatments and may make milestone and royalty payments.
- Vertex Pharmaceuticals: licenses Editas gene-editing technology for medicines targeting inherited blood disorders and pays annual license fees.
- Immatics: collaborates with Editas on gene-edited immune-cell treatments for cancer.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1The business depends heavily on EDIT-401, its lead medicine, and on advancing it from preclinical research into human trials.
- 2Editas licenses important gene-editing patents from universities and research institutions; those agreements require payments and compliance with their terms.
- 3It relies on outside manufacturers and service providers for research materials and planned clinical trials, and on partners and investors for funding.
Wat er mis kan gaan
- 1EDIT-401 has not yet established safety or effectiveness in people; failure or delay in its development could significantly affect the business.
- 2Gene-editing patents and licenses are subject to disputes and challenges, which could limit Editas's rights to use or license important technology.
- 3Editas has no medicine-sale revenue and needs substantial funding; if it cannot raise money or receive partner payments, it may have to cut or delay research and development.
Over Editas Medicine, Inc.
Editas develops medicines that change deoxyribonucleic acid (DNA) to treat disease. Its CRISPR (clustered regularly interspaced short palindromic repeats) technology uses a guide molecule to direct an enzyme to a chosen DNA location. Its lead medicine, EDIT-401, is being prepared for early human testing to lower low-density lipoprotein (LDL) cholesterol; the company also licenses its technology and works with drug companies on research programs.
- Hoofdkantoor
- Cambridge, Massachusetts
- Opgericht in
- 2013
- Genoteerd aan
- Nasdaq
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van Editas Medicine, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
